Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Ticker
GILD
Exchange
Nasdaq
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$207.97B
52-week range
$116.88 - $176.58

Valuation

Share price
$167.58 (close of Nov 16, 2026)
P/E (TTM)
-53.88x
Price to book
16.05x
Price to free cash flow
15.09x
Enterprise value
$227.76B
Book value per share
$10.44

Price performance

PeriodChange
1 day-0.30%
5 days-1.03%
1 month+7.29%
3 months+21.12%
6 months+29.33%
Year to date+36.53%
1 year+34.04%
3 years+124.88%
5 years+150.53%
10 years+120.50%
All time+26,381.76%

Short interest

As of
Oct 30, 2026
Short % of float
1.72%
Shares short
21.27M
Days to cover
3.18
Change since prior report
+4.94%
Source
FINRA consolidated short interest

Members of Congress who disclosed GILD trades

Tommy Tuberville · Josh Gottheimer · Marjorie Taylor Greene · Jared Moskowitz · Jefferson Shreve · Val Hoyle · Alan Armstrong · Carol Miller · John Boozman

Super investors holding GILD

Dodge & Cox (Dodge & Cox Funds) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · John Rogers (Ariel Investments LLC) · Mairs & Power (Mairs & Power Inc)

Profitability and growth

Return on equity
37.62%
Return on invested capital
18.37%
Return on assets
14.42%
Return on capital employed
21.23%
Gross margin
78.83%
Net margin
28.90%
EBITDA margin
43.45%
Revenue growth
2.40%
Free cash flow growth
-8.24%

Cash flow and balance sheet

Free cash flow yield (TTM)
6.63%
Current ratio
1.38x
Net debt to EBITDA
15.32x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$29.44B
Cost of revenue
$6.23B
Gross profit
$23.21B
EBITDA
$12.79B
Net income
$8.51B
Earnings per share
$6.84
Research and development
$5.80B
Interest expense
$1.02B
Shares outstanding
1.24B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$29.44B$23.21B$8.51B$6.84
2024-12-31$28.75B$22.50B$480.00M$0.38
2023-12-31$27.12B$20.62B$5.67B$4.54
2022-12-31$27.28B$21.62B$4.59B$3.66
2021-12-31$27.30B$20.70B$6.22B$4.96
2020-12-31$24.69B$20.12B$123.00M$0.10
2019-12-31$22.45B$17.77B$5.39B$4.24
2018-12-31$22.13B$17.27B$5.46B$4.20
2017-12-31$26.11B$21.74B$4.63B$3.54
2016-12-31$30.39B$26.13B$13.50B$10.08

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3178.83%28.90%37.62%18.37%
2024-12-3178.26%1.67%2.49%3.16%
2023-12-3176.04%20.89%24.90%13.32%
2022-12-3179.26%16.83%21.65%13.10%
2021-12-3175.82%22.80%29.55%16.22%
2020-12-3181.48%0.50%0.68%4.95%
2019-12-3179.18%23.99%23.78%8.94%
2018-12-3178.07%24.65%25.33%11.87%
2017-12-3183.26%17.73%22.57%13.07%
2016-12-3185.98%44.43%69.73%30.68%

Cash and debt by year

Period endCashDebt
2025-12-31$7.56B$22.13B
2024-12-31$9.99B$24.90B
2023-12-31$6.08B$23.19B
2022-12-31$5.41B$22.96B
2021-12-31$5.34B$25.18B
2020-12-31$6.00B$28.64B
2019-12-31$11.63B$22.09B
2018-12-31$17.94B$24.57B
2017-12-31$7.59B$30.80B
2016-12-31$11.89B$26.35B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$9.46B$894.00M
2024-12-31$10.30B$835.00M
2023-12-31$7.42B$766.00M
2022-12-31$8.34B$637.00M
2021-12-31$10.80B$635.00M
2020-12-31$7.52B$643.00M
2019-12-31$8.32B$636.00M
2018-12-31$7.48B$845.00M
2017-12-31$11.31B$638.00M
2016-12-31$16.30B$380.00M

Dividend history

Most recent payment
Sep 15, 2026
Paid in the last twelve months
$3.25
Payment dateDividend per share
2026-09-15$0.82
2026-06-15$0.82
2026-03-13$0.82
2025-12-15$0.79
2025-09-15$0.79
2025-06-13$0.79
2025-03-14$0.79
2024-12-13$0.77

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$2.17
2026-08-04Jun 2026-$7.07
2026-05-07Mar 2026$1.89
2026-02-10Dec 2025$1.87
2025-10-30Sep 2025$2.15
2025-08-07Jun 2025$1.95
2025-04-24Mar 2025$1.82
2025-02-11Dec 2024$1.67

Filings and sources

Company website
gilead.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Pfizer Inc (PFE) · Amgen Inc (AMGN) · Bristol Myers Squibb Co (BMY) · AstraZeneca plc (AZN) · Biogen Inc. (BIIB) · Novartis AG (NVS) · Organon & Co. (OGN) · Merck & Co., Inc. (MRK)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades